XML 25 R13.htm IDEA: XBRL DOCUMENT
v3.20.2

INVESTMENTS IN NON-MARKETABLE SECURITIES | 6 Months Ended
--- | ---
Sep. 30, 2020
ASU 2016-01 Transition [Abstract] |
Cost-method Investments, Description [Text Block] | NOTE 7 – INVESTMENTS IN NON-MARKETABLE SECURITIES
|  | (in thousands) |
|  | As of September 30, 2020 ($) |  |  | As of March 31, 2020 ($) |
Investment in equity shares of unlisted company |  |  | 12 |  |  |  | 11 |
Investment in Evolve I (i) |  |  | 249 |  |  |  | - |
Total |  |  | 261 |  |  |  | 11 |
(i) | On May 12, 2020, the Company completed an investment under the terms of the Share Subscription Agreement (“SSA”) with Evolve I, Inc., a Washington corporation (“Evolve”), by transferring part of the consideration to Evolve. As of September 30, 2020, the Company owns approximately 19.8% interest in Evolve.
The Company regularly reviews its investment portfolio to determine if any security is other-than-temporarily impaired, which would require the Company to record an impairment charge in the period.

X
- References No definition available. + Details
Name: | us-gaap_Asu201601TransitionAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for investments accounted for under the cost-method. The carrying amount of such investments may be adjusted, for example, distributions in excess of cost (return of capital) or for other-than-temporary impairments. The cost method and lower-of-cost or market, an adaptation of the cost method, is generally followed for most investments in noncontrolled corporations, in some corporate joint ventures, and to a lesser extent in unconsolidated subsidiaries in which the entity does not have the ability to exercise significant influence. + References No definition available. + Details
Name: | us-gaap_CostMethodInvestmentsDescriptionTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration